So many small/mid-cap biotechs are buyout candidates, I wouldn’t know where to start a list.
Among large caps, I would argue that BMY probably won’t be acquired in the next couple of years. A new CEO is starting in May, and BMY seems very with its portfolio, pipeline, and New York base.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”